Billionaire Stanley Druckenmiller Sold All of His Palantir and Has Piled Into This High-Flying Drug Stock for 4 Consecutive Quarters

Core Viewpoint - Stanley Druckenmiller, the billionaire head of Duquesne Family Office, has exited his position in Palantir Technologies, a leading AI stock, and shifted his focus to Teva Pharmaceutical Industries, which is considered one of the cheapest pharmaceutical stocks available [1][6][20] Investment Activity - Druckenmiller has completely sold his stake in Palantir, reducing his holdings from nearly 770,000 shares at the end of June 2024 to zero by the end of March 2025 [9][10] - Over the past year, Druckenmiller has added 45 securities to Duquesne's portfolio, with Teva being a significant focus, now ranking as the second-largest holding by market value [15][16] Palantir Technologies - Palantir has experienced a remarkable return of nearly 2,700% since the beginning of 2023, driven by its core platforms, Gotham and Foundry, which have unique value propositions [7][8] - Despite its strong performance, Palantir's valuation has raised concerns, with a price-to-sales (P/S) ratio around 140, significantly higher than historical norms for tech stocks [12][11] - The company has consistently exceeded Wall Street's sales and profit expectations, achieving recurring profitability ahead of estimates [9] Teva Pharmaceutical Industries - Teva's stock has gained 87% over the past two years, recovering from previous challenges, including overpayment for Actavis and litigation related to the opioid crisis [16][17] - A $4.25 billion settlement regarding opioid litigation has been agreed upon, alleviating legal uncertainties for Teva [17] - Teva is shifting focus towards brand-name drug development, with projected sales of its drug Austedo expected to reach around $2 billion in 2025 [18] - The company has significantly reduced its net debt and operating expenses, positioning itself for potential growth and earnings multiple expansion [19][20]